Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Abpro Corporation
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
With its new fund for companies emerging from Foresite Labs, Foresite Capital has raised more than $1bn in new venture capital during the past year to back life science and health care innovation.
Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.
Following a positive Phase III data readout for KX2-391, Athenex requests dissolution of its recent deal conferring rights to the drug in China to Chongqing Jingdong Junzhuo. TaiwanJ licenses Asian rights outside its home market for JK-122 to Newsoara.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries